ReproCELL Incorporated
Tokyo Stock ExchangeTotal Valuation
ReproCELL Incorporated carries a market capitalization of 12.34B, placing it among publicly traded companies globally. Its enterprise value stands at 5.67B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 12.34B |
| Enterprise Value | 5.67B |
Share Statistics
ReproCELL Incorporated currently has 94.23M shares outstanding.
| Shares Outstanding | 94.23M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 8.47, and the price-to-book ratio stands at 4.31.
| PE Ratio | N/A |
| PS Ratio | 8.47 |
| PB Ratio | 4.31 |
| P/TBV Ratio | 1.24 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 4.43 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
ReproCELL Incorporated maintains a current ratio of 9.40, meaning it holds 9.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 9.40 |
| Quick Ratio | 8.04 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -4.52 |
| Return on Assets (ROA) | -1.03 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.61 |
Taxes
| Income Tax | 1.42M |
| Effective Tax Rate | N/A |
Stock Price Statistics
ReproCELL Incorporated's stock has declined approximately -31.52174% over the past 52 weeks. The 50-day moving average sits at 142.80, while the 200-day moving average is 162.82.
| Beta (5Y) | N/A |
| 52-Week Price Change | -31.52174% |
| 50-Day Moving Average | 142.80 |
| 200-Day Moving Average | 162.82 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, ReproCELL Incorporated generated 1.28B in revenue and converted that into -92.22M in net income, yielding earnings per share of -1.03. EBITDA reached -167.73M, while operating income came in at -167.73M.
| Revenue | 1.28B |
| Gross Profit | 622.13M |
| Operating Income | -167.73M |
| Pretax Income | -90.80M |
| Net Income | -92.22M |
| EBITDA | -167.73M |
| EBIT | -167.73M |
| Earnings Per Share (EPS) | -1.03 |
Balance Sheet
Total book value stands at 2.51B, with working capital of 5.40B providing operational flexibility.
| Cash & Cash Equivalents | 5.17B |
| Total Debt | N/A |
| Net Debt | -3.05B |
| Equity (Book Value) | 2.51B |
| Book Value Per Share | 28.07 |
| Working Capital | 5.40B |
Margins
ReproCELL Incorporated operates with a gross margin of 48.62, reflecting its pricing power and cost economics. The operating margin of -13.11 and net profit margin of -7.21 provide insight into operational efficiency.
| Gross Margin | 48.62 |
| Operating Margin | -13.11 |
| Pretax Margin | -7.10 |
| Profit Margin | -7.21 |
| EBITDA Margin | -13.11 |
Stock Splits
ReproCELL Incorporated's most recent stock split took place on August 28, 2013 with a 1:5 split ratio.
| Last Split Date | 8/28/2013 |
| Split Ratio | 1:5 |
Scores
ReproCELL Incorporated posts an Altman Z-Score of 10.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 10.32 |